Skip to main content
. 2021 Apr 30;7(4):e25075. doi: 10.2196/25075

Table 2.

Characteristics of patients by outcome of hospitalization in a retrospective cohort from a telemedicine monitoring program in Atlanta, Georgia, with enrollment between March 24 and May 26, 2020.

Characteristic Nonhospitalized patients (n=461) Hospitalized patients (n=35) Unadjusted hazard ratio (95% CI) P value
Age (years), mean (95% CI) 46.7 (45.4-48.1) 59.1 (55.2-63.1) N/Aa <.001b
Days from first symptom to visit, mean (95% CI) 9.4 (8.6-10.2) 7.4 (5.2-9.6) N/A .16b
Days from COVID-19 test to visit, mean (95% CI) 3.7 (3.4-4.0) 2.7 (1.9-3.5) N/A .09b
Follow-up duration (days), mean (95% CI) 13.4 (12.6-14.3) 8.5 (5.0-12.1) N/A .003b
Age category (years), n (%)

18-29 (n=78) 78 (16.9) 0 (0) N/A c
30-39 (n=84) 81 (17.6) 3 (8.6) Reference
40-49 (n=106) 103 (22.3) 3 (8.6) 0.71 (0.14-3.53) .68
50-59 (n=115) 105 (22.8) 10 (28.6) 2.16 (0.59-7.85) .24
60-69 (n=84) 68 (14.8) 16 (45.7) 4.89 (1.42-16.79) .01
≥70 (n=29) 26 (5.6) 3 (8.6) 2.32 (0.47-11.52) .31
Race, n (%)

Other (n=147) 141 (30.6) 6 (17.1) Reference
Black (n=252) 234 (50.8) 18 (51.4) 1.59 (0.63-4.01) .33
White (n=97) 86 (18.7) 11 (31.4) 2.59 (0.96-7.01) .06
Gender, n (%)

Female (n=330) 311 (67.5) 19 (54.3) Reference
Male (n=166) 150 (32.5) 16 (45.7) 1.76 (0.91-3.43) .10
Comorbidities, n (%)

Asthma (n=73) 67 (14.5) 6 (17.1) 1.07 (0.44-2.59) .88
Cancer or malignancy (n=37) 34 (7.4) 3 (8.6) 1.07 (0.33-3.50) .91
Chronic obstructive pulmonary disease (n=5) 4 (0.9) 1 (2.9) 2.58 (0.35-18.84) .35
Coronary artery disease (n=24) 18 (3.9) 6 (17.1) 3.71 (1.54-8.96) .004
Diabetes (n=69) 56 (12.1) 13 (37.1) 3.59 (1.81-7.12) <.001
Drug abuse or addiction (n=4) 3 (0.7) 1 (2.9) 4.29 (0.59-31.45) .15
Heart failure (n=10) 6 (1.3) 4 (11.4) 5.84 (2.06-16.55) <.001
Hypertension (n=175) 157 (34.1) 18 (51.4) 1.75 (0.90-3.40) .10
Immune suppression (n=30) 30 (6.5) 0 (0) 0.05 (0.00-16.22) .30
Lung disease (n=17) 14 (3.0) 3 (8.6) 2.10 (0.64-6.88) .22
Obesity reportedd (n=147) 130 (28.2) 17 (48.6) 2.27 (1.17-4.41) .02
Obesity correctede (n=212) 186 (87.7) 26 (74.3) 3.83 (1.80-8.18) <.001
Renal disease (n=16) 13 (2.8) 3 (8.6) 2.35 (0.72-7.71) .16
Number of diagnoses, n (%)

0 (healthy) (n=174) 170 (36.9) 4 (11.4) Reference
1 (n=158) 148 (32.1) 10 (28.6) 2.61 (0.82-8.34) .11
2 (n=91) 83 (18.0) 8 (22.9) 3.43 (1.03-11.40) .04
≥3 (n=73) 60 (13.0) 13 (37.1) 6.77 (2.20-20.83) <.001
Ability to self-isolate safely, n (%)

Adequate (n=409) 383 (83.1) 26 (74.3) Reference
Inadequate (n=9) 7 (1.5) 2 (5.7) 3.80 (0.90-16.05) .07
Unknown (n=78) 71 (15.4) 7 (20.0) Unknown
Severity of symptoms, n (%)

None or mild (n=316) 301 (65.3) 15 (42.9) Reference
Moderate (n=134) 121 (26.2) 13 (37.1) 1.79 (0.85-3.77) .13
Severe (n=9) 6 (1.3) 3 (8.6) 6.82 (1.95-23.83) .003
Unknown (n=37) 33 (7.2) 4 (11.4) Unknown
Symptoms course, n (%)

Improving (n=264) 253 (54.9) 11 (31.4) Reference
Stable (n=155) 143 (31.0) 12 (34.3) 1.84 (0.81-4.17) .15
Worsening (n=31) 24 (5.2) 7 (20.0) 5.43 (2.10-14.03) <.001
Unknown (n=46) 41 (8.9) 5 (14.3) Unknown
Tier, n (%)

1 (n=237) 234 (50.8) 3 (8.6) Reference
2 (n=185) 170 (36.9) 15 (42.9) 5.29 (1.53-18.32) .009
3 (n=74) 57 (12.4) 17 (48.6) 16.24 (4.74-55.59) <.001

aN/A: not applicable; unadjusted hazard ratio was not calculated.

bP value was based on a t test.

cNot calculated, either because the unadjusted hazard ratio value was not calculated or was unknown or because the characteristic was used as reference.

dBMI ≥30 recorded in Virtual Outpatient Monitoring Clinic (VOMC) intake note by provider; BMI is calculated as weight in kilograms divided by height in meters squared.

eBMI ≥30 determined by height and weight data in electronic medical record or recorded in VOMC intake note; BMI is calculated as weight in kilograms divided by height in meters squared.